Type of Study:
Newly diagnosed adolescents 8-17 years old with Type 1 diabetes
8 to 17 years old, Male and Female
Participants will receive at no cost: study product, study materials and study-specific procedures
The Protect study will determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks.